Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.66 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039701 | 0.97 | PTGS1 (0.66) | PTGS2PTGS1RXRARXRBRXRG | |
| SCHEMBL5039720 | 0.88 | PTGS1 (0.62) | PTGS2PTGS1KMT2APSEN1PSEN2 | |
| SCHEMBL4827831 | 0.86 | PTGS2 (0.67) | PTGS2PTGS1KMT2A | |
| SCHEMBL6270908 | 0.86 | HDAC4 (0.51) | PTGS2PTGS1RXRARXRBRXRG | |
| SCHEMBL3729385 | 0.84 | PTGS2 (0.58) | PTGS2PTGS1KMT2A | |
| SCHEMBL183940 | 0.82 | KMT2A (0.67) | PTGS2PTGS1KMT2AMEN1 | |
| SCHEMBL5544986 | 0.82 | KMT2A (0.67) | PTGS2PTGS1KMT2AMEN1 | |
| SCHEMBL5537242 | 0.82 | KMT2A (0.67) | PTGS2PTGS1KMT2AMEN1 | |
| SCHEMBL10998865 | 0.82 | KMT2A (0.53) | PTGS2PTGS1RXRARXRBRXRG | |
| SCHEMBL31261540 | 0.81 | PTGS2 (0.69) | PTGS2PTGS1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001486-A2 | BISPHOSPHONATE COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070275931-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007109585-A2 | BISPHOSPHONATE COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275931-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS | FDPS, GGPS1, FNTB | PTGS2 2039/4885PTGS1 1401/4885RXRA 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.